Drug Manufactureers: Allergan (NYSE:AGN), POZEN (NASDAQ:POZN), DURECT Corporation (NASDAQ:DRRX), Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY)

Allergan, Inc. (NYSE:AGN) said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine aerosol but had separately approved a treatment for diabetic macular edema. Allergan, Inc. (NYSE:AGN) net profit margin is 18.50% and weekly performance is -0.83%. On last trading day company shares ended up $169.13. Analysts mean target price for the company is $187.43. Allergan, Inc. (NYSE:AGN) distance from 50-day simple moving average is 2.65%.

POZEN Inc. (POZN) reported that its new drug application (NDA) for its drugs PA8140/PA32540 has been resubmitted to the Food and Drug Administration (FDA). According to regulations, the FDA has 14 days to inform Pozen whether its application will be accepted. If the application is accepted, then under the Prescription Drug User Fee Act (PDUFA), the FDA will decide whether the review will require two months or six months. POZEN Inc. (NASDAQ:POZN) shares advanced 0.22% in last trading session and ended the day on $9.25. POZN its return on assets is -13.60%. POZEN Inc. (NASDAQ:POZN) quarterly performance is 17.24%.

DURECT Corporation (NASDAQ:DRRX) announced that it had entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $20 million. The loan has a fixed interest rate of 7.95% per annum with interest only payments for the first 18 months and repayment of all principal and interest by July 1, 2018. In addition, the Company paid a $150,000 facility fee at closing and, at maturity or earlier termination, the Company must pay Oxford an additional one-time payment equal to 8% of the initial principal amount of the term loan. The Company may use the proceeds of the Loan Agreement for general working capital and to fund its business requirements. DURECT Corporation (NASDAQ:DRRX) shares moved down -1.16% in last trading session and was closed at $1.70, while trading in range of $1.70-$1.74. DURECT Corporation (NASDAQ:DRRX) year to date performance is -1.73%.

TheStreet upgraded shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) ended the last trading day at $44.02. Company weekly volatility is calculated as 0.96% and price to cash ratio as 14.72. Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) showed a positive weekly performance of 5.44%.